BioInvent has carried out a directed issue
BioInvent has carried out a directed placement of new shares of approximately MSEK 300 to international and Swedish institutional investors.
BioInvent is a clinical stage company focused on the development of novel, first-in-class immuno-modulatory antibodies for the treatment of cancer. BioInvent’s shares are listed on Nasdaq Stockholm (BINV).
BioInvent was represented by Mannheimer Swartling.